Recombinant human endostatin - Simcere

Drug Profile

Recombinant human endostatin - Simcere

Alternative Names: Endostar; Endu; rh-endostatin; YH-16

Latest Information Update: 27 Jan 2016

Price : $50

At a glance

  • Originator Simcere Pharmaceutical Group
  • Developer Peking University; Simcere Pharmaceutical Group
  • Class Angiostatic proteins; Antineoplastics; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Brain metastases; Colorectal cancer; Gastric cancer; Malignant ascites; Malignant melanoma; Malignant pleural effusion; Oesophageal cancer; Osteosarcoma; Small cell lung cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Aug 2015 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable) in China (SC) (NCT02652234)
  • 03 Nov 2014 Simcere plans a phase III trial for Squamous cell lung cancer (Combination therapy, Late-stage disease) in China (NCT02283476)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top